U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.36%)
     
  • BTC-USD

    34,199.15
    -190.85 (-0.55%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMD

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Graybug Vision Inc (NASDAQ: GRAY) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet AMD).

  • GB-102 is a proprietary formulation of sunitinib malate injected twice a year intravitreally.

  • The ALTISSIMO full-data analysis focused on the GB-102 1mg arm compared to aflibercept and the pre-enrollment period, excluding results from the GB-102 2mg arm.

  • Overall, GB-102 1mg was safe and well-tolerated. No drug-related serious adverse events or vision-threatening inflammation were reported.

  • The majority of drug-related adverse events were mild to moderate. The particle migration to the anterior chamber in patients treated with GB-102 1mg was reduced by 79% compared to GB-102 1mg patients in the ADAGIO Phase 1/2a trial (4/51 injections vs. 3/8), and no surgical interventions were required.

  • As previously reported, patients in the GB-102 1mg trial arm (n=21) had a median time to first supportive therapy of five months, and 48% of patients did not require supportive treatment for at least six months.

  • An additional analysis showed the injection frequency was reduced by 58% compared to patients' treatment before enrollment in the trial.

  • The company is also working on a GB-401 implant program for glaucoma that will enter a Phase 1 trial in the first half of 2022.

  • Graybug expects to report the results from the ongoing six-month extension period of ALTISSIMO by the end of this year.

  • The company also said it would pause developing GB-103 and GB-102 for diabetic macular edema and utilize the cash to advancing GB-401 through Phase 1 clinical development.

  • The company's management will host a webcast and conference call at 8 a.m. ET today to discuss the ALTISSIMO clinical results.

  • Price Action: GRAY shares are trading 7.4% lower at $4.38 on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.